• Chronic Myeloid Leukemia
• Myelodysplastic Syndromes

His primary commitment is to bring new agents/combinations to the clinic for improving outcome in patients with these diseases. While doing this, he has taken to the clinic ideas that have emerged out of the works of translational science leaders in the department of Leukemia. He has opened more than thirty investigator-initiated or industry-sponsored clinical trials in his area of interest and has an active translational research program on autophagy and epigenetic targets, for example BRD4.